Abstract
Lentivirus-based vectors have the potential to transduce non-dividing primary stem cells. However, primary cells tend to be less susceptible to manipulation and require a high concentration of virus inoculum. Furthermore, increasing the concentration of the lentivirus inoculum may raise safety risks. Therefore, to develop a technique that allows high transduction efficiency at low multiplicities of infection (MOIs), we optimized a lentivirus-based system for cell lines and primary cells by determining the best condition using various parameters. When progenitor cell assays were conducted using human CD34+ bone marrow and mononuclear cells, the transduction condition yielded a great number of eGFP+ colonies with lower-dose viral inocula compared to that of current lentivirus-based transduction technologies. In conclusion, this system is anticipated to produce stable expression of a gene introduced into primary cells for preclinical studies with lower safety risks.
Original language | English |
---|---|
Pages (from-to) | 281-288 |
Number of pages | 8 |
Journal | Biotechnology letters |
Volume | 37 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2015 Feb |
Keywords
- CD34 bone marrow
- Gene therapy
- Hematopoietic cells
- Progenitor cell assay
- Pseudotyped lentiviral vector
- Transduction efficiency
- Viral inoculum
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Applied Microbiology and Biotechnology